Amgen 3Q Revenues: $3.6 billion (flat) 3Q Earnings: $201 million (-81%) YTD Revenues: $11.0 billion (+6%) YTD Earnings: $2.3 billion (+10%) Comments: Overall U.S. sales diminished 2% as Medicare reimbursement for Aranesp was lowered, while dosing questions impaired EU sales of the drug. Enbrel sales were up 16% to $821 million. Earnings took a $590 million hit to write off in-process R&D from a pair of acquisitions, as well as a $293 million charge as part of the company&#8217...